Search | OpenScholar

Search results

1963 results found

Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. Front Neurol. 2020;11:576117.

Publication: Journal Article

Hauser, RA, and . 2020. “Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. Front Neurol. 2020;11:576117.”. Front Neurol.

A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci 2018;128:619-626.

Publication: Journal Article

Lew, MF, A Breashear, K Dashtipour, S Isaacson, RA Hauser, P Maisonobe, D Snyder, and W Ondo. 2018. “A 500 U/2 mL Dilution of AbobotulinumtoxinA Vs. Placebo: Randomized Study in Cervical Dystonia. Int J Neurosci 2018;128:619-626.”. Int J Neurosci.

Hauser RA, Truong D. Tardive dyskinesia: Out of the shadows. J Neurol Sci 2018;389:1-3.

Publication: Journal Article

“Hauser RA, Truong D. Tardive Dyskinesia: Out of the Shadows. J Neurol Sci 2018;389:1-3.”. 2018. J Neurol Sci.

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 2018;17:804-822.

Publication: Journal Article

Charvin, D, R Medori, RA Hauser, and O Rascol. 2018. “Therapeutic Strategies for Parkinson Disease: Beyond Dopaminergic Drugs. Nat Rev Drug Discov 2018;17:804-822.”. Nat Rev Drug Discov.

Hauser RA. Help cure Parkinson's disease: please don't waste the Golden Year. NPJ Parkinsons Dis 2018;4:29.

Publication: Journal Article

“Hauser RA. Help Cure Parkinson’s Disease: Please Don’t Waste the Golden Year. NPJ Parkinsons Dis 2018;4:29.”. 2018. NPJ Parkinsons Dis.

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol 2017;74:216-224.

Publication: Journal Article

Schapira, AH, SH Fox, RA Hauser, J Jankovic, WH Jost, C Kennedy, J Kulisevsky, R Pahwa, W Poewe, and R Anand. 2017. “Assessment of Safety and Efficacy of Safinamide As a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol 2017;74:216-224.”. JAMA Neurol.

Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. Am J Cardiol 2017;119:1111-1115.

Publication: Journal Article

White, WB, RA Hauser, GJ Rowse, A Ziemann, and LA Hewitt. 2017. “Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. Am J Cardiol 2017;119:1111-1115.”. Am J Cardiol.

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). Ann Clin Transl Neurol 2017;4:360-368.

Publication: Journal Article

Biglan, KM, D Oakes, AE Lang, RA Hauser, K Hodgeman, B Greco, J Lowell, et al. 2017. “A Novel Design of a Phase III Trial of Isradipine in Early Parkinson Disease (STEADY-PD III). Ann Clin Transl Neurol 2017;4:360-368.”. Ann Clin Transl Neurol.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology 2017;89:2495-2502.

Publication: Journal Article

Schobel, SA, G Palermo, P Auinger, JD Long, S Ma, OS Khwaja, D Trundell, 2CARE Huntington Study Group Investigators, and . 2017. “Motor, Cognitive, and Functional Declines Contribute to a Single Progressive Factor in Early HD. Neurology 2017;89:2495-2502.”. Neurology.

Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord 2016;31:1366-72.

Publication: Journal Article

Hauser, RA, CW Olanow, B Dzyngel, T Bilbault, H Shill, S Isaacson, J Dubow, and A Agro. 2016. “Sublingual Apomorphine (APL-130277) for the Acute Conversion of OFF to ON in Parkinson’s Disease. Mov Disord 2016;31:1366-72.”. Mov Disord.